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Aim: This cross-sectional study assessed cytokine levels in peri-implant crevicular fluid (PICF)/ gingival 
crevicular fluid (GCF) and a selection of subgingival/submucosal plaque bacteria from clinically healthy or diseased 
sites in the same individuals.  
Material and Methods: Samples from 97 implants/teeth (58 implants: 19 healthy, 20 mucositis, 19 peri-
implantitis; 39 natural teeth: 19 healthy, 12 gingivitis, 8 periodontitis) in 15 systemically healthy patients were 
investigated by immunoassay, real-time PCR. Samples were obtained first and then probing depth, clinical 
attachment level, bleeding on probing, plaque index scores, keratinized tissue width were recorded. Data were 
analyzed by Wilcoxon, Mann-Whitney and permutation tests on dependent, independent, mixed dependent and 
independent samples and Spearman correlation.  
Results: Interleukin-1beta levels were significantly higher in PICF samples of healthy implants than in 
GCF samples of healthy teeth (p=0.003), soluble activator of nuclear factor Kappa-B (sRANKL) concentrations 
were significantly higher in gingivitis than mucositis group (p=0.004). The biomarker levels were similar in peri-
implantitis and periodontitis groups (p>0.05). Actinomyces naeslundi and Streptococcus oralis levels were 
significantly higher in healthy implant group than healthy teeth (p<0.05). Prevotella intermedia and Treponema 
denticola levels were lower in mucositis group than in gingivitis group (p<0.05). Prevotella oralis and S. oralis 
levels were significantly higher in the periodontitis group (p<0.05) and T. denticola levels were significantly higher 
in the peri-implantitis group (p<0.05).  
Conclusion: There were many similarities but crucially some differences in biomarker levels  (IL-1β and 
sRANKL) and bacterial species between peri-implant and periodontal sites in the same individuals suggesting 
similar pathogenic mechanisms.  
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Inflammatory reactions around dental implants may affect only the peri-implant mucosa leading 
mucositis or also the peri-implant hard tissues leading to peri-implantitis.1,2 Peri-implant 
mucositis is characterized by bleeding on probing without bone loss, whereas peri-implantitis is 
defined as loss of supporting bone around osseointegrated implants that is often associated with 
pocket formation, suppuration and mobility of the implant.3 
The prevalence of peri-implant mucositis varies between 36.3-64.6% and peri-implantitis 
between 8.9-47.1%.4 Peri-implant diseases may disturb esthetics as well as function of the 
implants and progressive bone loss may cause implant failure.5 Therefore, early detection and 
treatment of peri-implant diseases is of utmost importance. Various clinical measures including 
probing depth (PD), bleeding on probing (BOP), and plaque index (PI) are used to assess peri-
implant health.6 Inflammatory process of peri-implant tissues has been examined in peri-implant 
crevicular fluid (PICF) samples.7 PICF is a valuable biofluid that is easily obtained by non-
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invasive methods for examining biochemical mediators with potential for early detection of peri-
implant inflammatory diseases. Recent studies have demonstrated that various biomarkers in 
PICF are selectively upregulated at sites of inflammation and tissue breakdown compared with 
healthy sites.8,9  
Major differences between gingivitis and periodontitis sites are presence of a dysbiotic 
microbiota and a susceptible host.10,11 Dysbiosis can either be the cause or the consequence of 
disease. Homeostasis is a condition of equilibrium or stability in a known system.12 Recently, it 
has been proposed that periodontitis fundamentally represents disruption of host-microbial 
homeostasis by dysbiosis of the periodontal microbiota.10 Periodontal pathogens and their 
virulence factors stimulate the release of immunological biomarkers such as tumor necrosis 
factor alpha (TNF-α), interleukin-1beta (IL-1β), IL-6, IL-17, receptor activator of nuclear factor 
kappa-B ligand (RANKL)13. Socransky et al.14 stated that mainly anaerobic gram-negative 
bacterial species such as Tannerella forsythia (T. forsythia), Treponema denticola (T. denticola), 
and Porphyromonas gingivalis (P. gingivalis) are associated with periodontal destruction. So far, 
the levels of key biologic mediators in gingival crevicular fluid (GCF) and PICF samples have 
been comparatively investigated in few studies.15,16 It was hypothesized that possible differences 
in cytokine content and/or bacterial species between healthy and diseased sites may reveal 
similar factors acting in pathogenesis of periodontitis and peri-implantitis. Therefore, the aim of 
the present study was to comparatively assess the levels of IL-1β, IL-17A, IL-17F, IL-17E, 
sRANKL, and osteoprotegerin (OPG) in PICF/GCF samples and presence of A. 
actinomycetemcomitans, Actinomyces naeslundi, Fusobacterium nucleatum, P. gingivalis, 
Prevotella intermedia, Streptococcus mutans, T. denticola T. forsythia and Veillonella dispar in 
subgingival/submucosal plaque samples from healthy and diseased teeth and implants in the 
same individuals.  
MATERIALS AND METHODS 
Study Population 
Fifteen systemically healthy patients were recruited in this cross-sectional study at the 
Department of Periodontology, School of Dentistry, Ege University, İzmir, Turkey between 
January 2014 and September 2014. Participants were sequentially recruited among patients 
referred for periodontal/peri-implant disease treatment. Healthy and diseased sampling sites were 
matched both for the implants and natural teeth in the same individuals. The inclusion criteria 
were; being systemically healthy, having implant-supported prosthesis in function for at least 12 
months with at least one implant diagnosed with peri-implantitis based on: presence of at least 
one site with probing depth (PD) > 4 mm with bleeding on probing (BOP) and/or suppuration 
and radiographic evidence of bone loss ≥ 2 mm.4 Moreover, the participants were required to 
have clinical diagnosis of periodontitis based on: presence of PD > 4 mm, clinical attachment 
level (CAL) ≥ 3 mm, and BOP. Peri-implant mucositis was diagnosed on the presence of BOP 
without loss of supporting bone.3,4 Diagnosis of gingivitis was assigned, when there is BOP, PD 
<4 mm and no clinical sign of periodontitis was evident.17 Un-inflamed implant and tooth sites 
with PD< 3mm and CAL< 3mm were considered to be healthy. 
The exclusion criteria were presence of any known systemic disease, history of aggressive 
periodontitis, antibiotic and/or anti-inflammatory drug usage within the last 6 months before the 
start of the study, and presence of less than 16 teeth. This study was approved by the Institutional 
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Review Board, School of Medicine, Ege University (protocol no. 13-11.1/9). The study protocol 
was explained and written informed consent was received from each participant before 
enrolment in the study.  
Sampling sites were selected according to the health status of the peri-implant/periodontal 
tissues in the same individuals. Teeth with the most severe periodontal tissue destruction 
comparable with the peri-implantitis sites; and the most severely inflamed sites were included in 
the periodontitis/gingivitis groups. The investigated dental implants were of two brands∗∗†† with 
conical connection design.  
Clinical Periodontal Measurements 
PD, CAL, BOP, plaque index (PI) scores and keratinized tissue width (Kr TW) were recorded. 
The clinical periodontal and peri-implant examinations were performed by two periodontists, 
who were trained and calibrated initially and also at the 6th month of the study (ÖG, PG). The 
initial intra-examiner kappa values were 0.96 (PD) and 0.86 (CAL) for PG and 0.93 (PD) and 
0.79 (CAL) for ÖG. The interexaminer values were 0.92 (PD) and 0.75 (CAL). BOP was 
deemed positive if it occurred within 15 sec after probing. Presence of visible plaque was 
recorded dichotomously by visual examination.18 A periodontal probe‖ was used for 
measurement of PD and CAL at four sites (mesio-buccal, mid-buccal, disto-buccal, mid-lingual) 
of each tooth/implant present, except the third molars. Bite-wing radiographs were taken from all 
participants to determine the presence of bone loss around the dental implants.  
Biofluid and Plaque Sampling 
All samples were obtained before clinical periodontal recordings. GCF/PICF samples were 
obtained by the standard filter paper strips,¶ from the buccal aspects of the teeth/implants. Filter 
paper strips were placed in the gingival/peri-implant sulcus and left in place for 30 sec. Care was 
taken to avoid mechanical trauma, and strips visually contaminated with blood were discarded. 
Sample volumes were estimated with a calibrated instrument.# 
Before subgingival/submucosal plaque sampling, supragingival/supramucosal plaque was 
removed carefully by sterile curettes.‡‡ The site was then isolated using cotton rolls and gently 
dried with an air syringe to avoid contamination with saliva. Another sterile Gracey curette was 
inserted to the bottom of the sulcus/pocket and removed applying a slight force towards the root 
surface. The tip of the curette was then inserted in the microcentrifuge tube containing 0.5 mL of 
distilled water and shaken until the plaque was removed from the curette. All samples were 
immediately frozen and stored at -40°C until the laboratory analyses. 
Oral prophylaxis or nonsurgical periodontal treatment was not initiated before sample 
collection and then individuals were enrolled a periodontal treatment program as required.  
Measurement of sRANKL, OPG, IL-1β, IL-17A, IL-17F, IL-17E and Albumin in 
GCF/PICF Samples 
Commercial enzyme-linked immunosorbent assay (ELISA) kits were purchased for the 
measurement of OPG,†† sRANKL,‡‡ IL-17A,§§ IL-17E,‖‖ IL-17F,¶¶ IL-1β## and assays were 
carried out according to the manufacturers’ recommendations. The optical densities were read at 
450 nm with a background subtraction at 570 nm and the samples were compared with the 
standards. The minimum detection limits for the assays were; OPG, 7.56 pg/mL; sRANKL, 7.56 
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pg/mL; IL-1β, 0.39 pg/mL; IL-17A, IL-17F, 0.79 pg/mL; IL-17E and IL-17A/F, 1.59 pg/mL. 
Albumin levels were determined by ELISA as previously described.19 The biochemical data 
were expressed as total amounts per sampling time (pg/30sec) and also as concentrations 
(pg/µL). 
Preparation and Assessment of Genomic DNA 
A Gram positive DNA isolation kit*** was used to prepare genomic DNA from the pelleted 
microbes present in the GCF sample bacteria and from known quantities of laboratory strains of 
the target microorganisms.20 The amount of DNA and the purity was checked at 260 nm and 280 
nm (260/280 nm ratio =1.8-2.0=good DNA purity) using a spectrophotometer.††† The DNA in 
standards and plaque samples was measured by fluorimetric analysis.‡‡‡ The DNA content of the 
target species used to fix the copy number of its bacterial genome to use as standards for each 
real-time Quantitative Polymerase Chain Reaction (RT-QPCR) assay.   
Real-Time Quantitative Polymerase Chain Reaction 
A RT-QPCR assay using TaqMan chemistry§§§ was used for the detection and quantification of 
bacterial cell copy numbers in 1 µg of plaque DNA. The primers and probes selected for the 
following bacteria were as published in the sources shown: P. gingivalis, A. 
actinomycetemcomitans, P. intermedia, T. forsythia, F. nucleatum.21-24 T. denticola,25 A. 
naeslundi, S. oralis, and V. dispar26 were purchased.‖‖‖ On a thermal cycler¶¶¶ the TaqMAN 
assay PCR cycling parameters used were 10 min at 95°C, and 40 cycles of 30 sec at 95°C and 1 
min at 60°C. All primer sets were validated by running four serial 1/10 dilutions of the standard 
DNA and calculating the efficiency of the reaction (E) where E= (10 -1/slope)-1. All reaction 
efficiencies calculated were acceptable (between 91-104%). All primer sets failed to amplify the 
DNA purified from different microbial standards.  
Statistical Analysis 
Previous studies on sRANKL and OPG in GCF27 indicated that effect sizes (delta/sigma) > 2 
were acceptable and that n > 6 would be sufficient to achieve 90% statistical power in a 
parametric test. With regard to IL-17 cytokines in GCF28 n=15 may be sufficient to give 90% 
statistical power with an effect size >1.25. Although the intention was to make direct 
comparisons in the same individuals, there were repeat observations from some patients and 
missing observations from some others (Table 1). All samples were assayed separately, but in 
those individuals where more than one implant fell into the same category, these values were 
averaged. First, a Q-Q plot analysis indicated that the data were not normally distributed; 
therefore, distribution free statistical tests were used. Second, for the analysis of mixed 
dependent and independent data sets the approach described by Dubnicka et al.29 was used. In 
brief, where there was direct concordance in sample numbers between disease categories, the 
Wilcoxon test was used for dependent sample comparisons in the same individuals. Where all 
samples were entirely independent between disease categories as between gingivitis and 
periodontitis, the Mann-Whitney-U test was used to compare the differences between the 
parameters recorded. Where there was a mixture of dependent and independent samples, a Monte 
Carlo method of 1000 random data combinations was used in a Permutation test (based on the 
Wilcoxon test). A Bonferroni correction was used to adjust the P value. Spearman correlations 
were performed to evaluate the relationship between clinical and biochemical data. All tests were 
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performed at a significance level of α = 0.05. Statistical calculations were performed using the 
SPSS version 22.0### and R (R Project for Statistical Computing) statistical software packages. 
RESULTS 
GCF/PICF and subgingival/submucosal plaque samples were obtained from a total of 97 
implants/teeth (58 implants, 39 natural teeth) in 15 patients. The clinical variables are presented 
in Table 1. The clinical parameters were similar in the gingivitis and mucositis groups and in 
periodontitis and peri-implantitis groups (p>0.05). In the healthy implant group PD, CAL, BOP, 
and PI data were significantly higher than the healthy tooth group (p<0.0001; p=0.01; p=0.009 
and p=0.002, respectively).  
Biomarkers 
The biomarker data are outlined in Figure 1 and Figure 2. OPG total amounts and concentrations 
and albumin adjusted concentrations (data not shown) were significantly higher (p=0.042; 
p=0.010; and p=0.027, respectively) and IL-1β, sRANKL levels and sRANKL/OPG ratio were 
significantly lower in the healthy implant sites than those in the mucositis and peri-implantitis 
sites (p=0.001 and p=0.001, respectively). sRANKL/OPG ratios were significantly lower at the 
healthy implant sites than those at the mucositis and peri-implantitis sites (p=0.035 and p=0.008, 
respectively) (Fig. 1).  
OPG concentrations were significantly higher (p=0.031 and p=0.022, respectively); and IL-
1β levels, sRANKL levels and sRANKL/OPG ratios were significantly lower at the healthy teeth 
sites than those at the gingivitis and periodontitis sites (p=0.002 and p=0.018, respectively). IL-
1β concentrations were higher at the gingivitis sites than those in the healthy group (p=0.003). 
Comparisons of natural teeth and implants with similar clinical health state revealed significantly 
higher IL-1β levels in the healthy implant group than those in the natural teeth (p=0.003), 
significantly higher sRANKL concentrations at gingivitis than in the mucositis sites (p=0.004) 
(Fig. 1).  
The concentrations of IL-17A, IL-17-F, and IL-17E were similar at healthy and diseased sites 
(Fig. 2). There was no-significant difference in the concentrations of these cytokines in GCF 
with the exception of the IL-17E concentration, which was significantly lower at the gingivitis 
sites than at healthy tooth sites (p<0.05). The comparisons of peri-implantitis and periodontitis 
samples revealed similar levels and concentrations of the IL-17 family cytokines (Fig. 2).  
Microbiological Parameters 
The microbiological data are presented in Figure 3. The copy numbers of A. naeslundii, P. 
gingivalis, F. nucleatum and T. forsythia levels were significantly higher at the mucositis than 
the healthy implant sites (p<0.05). Numbers of F.nucleatum, P. gingivalis, P. intermedia and T. 
forsythia were significantly higher at the peri-implantitis sites than at the healthy implant sites 
(p<0.05). F. nucleatum, P. intermedia and T. denticola levels were significantly higher at 
gingivitis sites than at healthy teeth (p<0.05). S. oralis, T. denticola, F. nucleatum and T. 
forsythia levels were significantly greater at periodontitis sites than at healthy tooth sites 
(p<0.05). Periodontitis sites revealed significantly higher P. gingivalis, P. oralis and S. oralis 
levels than the gingivitis sites (p<0.05). A. naeslundii levels were significantly lower in the 
healthy implants than in the healthy teeth (p<0.05). P. intermedia, T. denticola levels were lower 
at the mucositis sites than at the gingivitis sites (p<0.05). P. oralis, S. oralis and T. denticola 
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levels were significantly higher in the periodontitis sites than in the peri-implantitis sites 
(p<0.05). 
Correlations  
At the implant sites, the amount of IL-1β and sRANKL/OPG ratio correlated positively with PD, 
(rho=0.497 and rho=0.293, respectively), and IL-1β concentration with PD (rho=0.228). There 
were significant negative correlations between OPG concentration and PD (rho=-0.387) and 
between the amounts of OPG at implant sites with PD (rho= -0.277). There was also a significant 
positive correlation between the IL-17A/IL-17E ratio and CAL (rho=0.323) at implant sites. 
PICF volume correlated significantly with IL-1β (rho=0.659), sRANKL (rho=0.533), and the 
RANKL/OPG ratio (rho=0.332).  
At tooth sites, significant positive correlations were found between the amount of IL-1β and 
PD (rho=0.511), the amount of sRANKL, sRANKL/OPG and PD (rho=0.375 and rho=0.397), 
IL-1β concentrations and CAL (rho=0.223). Significant negative correlations consisted of OPG 
concentration with PD (rho= -0.423), OPG levels with PD (rho= -0.348). GCF volume correlated 
with IL-1β (rho=0.742); sRANKL (rho=0.513); OPG (rho=- 372) and the RANKL/OPG ratio 
(rho=0.478). There were numerous significant correlations between the microbiological and 
clinical data (Table 2). Significant positive correlations were found at both tooth and implant 
sites between the PD and the presence of F. nucleatum, P. gingivalis, T. denticola and T. 
forsythia with the addition of A. actinomycetemcomitans and P. oralis at the tooth sampling sites. 
In contrast, S. oralis showed a negative correlation with PD at tooth sites. At implant sites, P. 
intermedia and A. naeslundii showed weak positive correlations with CAL while A. 
actinomycetemcomitans had a weak negative correlation with CAL (Table 2). 
P. gingivalis, F. nucleatum, and P. intermedia T. denticola, T. forsythia and V. dispar levels 
correlated positively with the amount of IL-1β. P. gingivalis, P. intermedia, T. denticola and T. 
forsythia with the amount of sRANKL and the sRANKL/OPG ratio (Table 3). Significant 
negative correlations were found between A. actinomycetemcomitans and the amount of 
sRANKL, sRANKL concentration and sRANKL/OPG ratio and P. gingivalis with OPG (Table 
3).  
DISCUSSION 
To the best of our knowledge, this is the first cross-sectional study evaluating the biomarkers and 
microbiological data in implants versus natural teeth matched with regard to the clinical health 
status in the same individuals. Implants and teeth from the same individuals have been studied 
before but little information on their disease status was provided.30 The present study was 
undertaken to investigate levels of IL-1β, IL-17, sRANKL, and OPG in GCF/PICF and presence 
and counts of A. actinomycetemcomitans, A. naeslundi, F. nucleatum, P. gingivalis, P. 
intermedia, S. mutans, T. denticola, T. forsythia and V. dispar around teeth and implants with 
different health status in the same individuals.  
Like other cross-sectional studies8,30,31,32 a major limitation is in relating the cause and effect 
of the disease and an accurate relationship between measurable parameters, however, strength of 
this type of investigation is the ability to survey a large number of parameters for potential 
associations. Another limitation of the present study is the rather low number of sampling sites 
available for periodontitis category to match with the peri-implantitis sites in the same 
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individuals. The approach of matching the different disease categories in the same individuals 
severely limited the number of patients eligible for the study. The major challenge this posed was 
that an exact match of healthy sites with the different disease categories was not possible; 
however, attempts were made to deal with this issue by carrying out the permutation analysis. An 
alternative approach could be combining the diseased groups at implants and teeth to compare 
with the corresponding healthy implants and teeth respectively, but this would have still resulted 
in a degree of mismatch and would have made the comparisons with the inflamed implant and 
tooth sites difficult because of the different level of disease at these locations.  
Implants with conical implant-abutment connection had negligible bacterial contamination 
due to the decreased microgap and microleakage under in vitro conditions. Microgap and 
microleakage act as a reservoir of bacteria and this may contribute to the establishment of peri-
implantitis.33 For standardization purposes, only implants with a conical connection design were 
included in this study. 
Pro-inflammatory cytokines induce alveolar bone resorption by increasing the expression of 
RANKL and reducing OPG in osteoblasts and stromal cells.34 Mogi et al.27 reported significantly 
greater ratio of RANKL/OPG in patients with periodontal disease. Vernal et al.35 found higher 
levels of RANKL in untreated patients with chronic periodontitis than healthy controls. An 
increased RANKL/OPG ratio was reported in GCF samples obtained from periodontitis sites 
compared to gingivitis/healthy sites.36 Rakic et al.8 found higher sRANKL levels in peri-
implantitis sites. However, Sarlati et al.9 reported similar data in the study groups. In their study, 
40 implants were categorized as clinically healthy, peri-implant mucositis and peri-implantitis 
according to the clinical and radiographic findings. Similar RANKL/OPG ratio was found in 
peri-implantitis sites and healthy controls,8,37 while Duarte et al.38 observed an increase in 
RANKL/OPG ratio in peri-implantitis. In the present study, the healthy implant group revealed 
significantly higher OPG total amounts and concentrations than the mucositis and peri-
implantitis groups; together with significantly lower sRANKL levels and sRANKL/OPG ratios. 
The present finding of significantly higher OPG concentration in healthy teeth than gingivitis 
and periodontitis groups is consistent with the existing literature.27,35 sRANKL concentrations 
were significantly higher in the present gingivitis than the mucositis group. A recent study 
reported significantly higher IL-1β levels in peri-implantitis sites compared to healthy implants.39 
Accordingly, we found significantly higher IL-1β levels in the peri-implantitis sites than in the 
healthy implants; also in the gingivitis, periodontitis than the healthy teeth sites. These findings 
provide further support for the previous studies suggesting that peri-implant and periodontal 
diseases have similar patterns in terms of host response and bone destruction. However, when 
natural teeth and implants are compared, IL-1β levels were significantly higher in the healthy 
implant group than the healthy teeth sites, and this in part contradicts the findings of a 
longitudinal study that showed elevated IL-1α levels at healthy tooth sites than at healthy implant 
sites40 and loosely in agreement with the cross sectional study by Recker et al.31 where IL-17A 
and TNF were higher at implant than at tooth sites. Furthermore, IL-1β and TNF levels were 
higher at implants than at teeth.32 According to the present findings, sRANKL concentrations 
were significantly higher at the gingivitis than at mucositis sites. This may be explained by a 
rather more prominent innate immune response at peri-implant sites than natural teeth without 
bone resorption. However, in the current study IL-1β, sRANKL and OPG levels were similar in 
the peri-implantitis and periodontitis groups.  
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IL-17 family of cytokines consists of IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (IL-25) and 
IL-17F. IL-17A synergizes with other cytokines, including IL-1β, TNF-α.41 IL-17A increases 
RANKL expression and concomitantly decreases OPG expression in osteoblastic cells in vitro 
and in vivo.42 IL-17F also plays a critical role in host defense upon bacterial and fungal infection 
by recruiting neutrophils and producing antimicrobial-peptides.43 The presence of IL-17A/F 
heterodimers substantially influences the potency, specificity and the spectrum of the activity of 
cytokines.44 In contrast with the other IL-17 family cytokines, IL-17E is an anti-inflammatory 
cytokine, which opposes the functions of IL-17A and IL-17F.45 Evidence for this role of IL-17E 
in the oral environment is manifested in experiments with oral epithelial cells. In the current 
study, IL-17E concentrations were significantly lower at gingivitis sites than at healthy sites but 
no significant differences were observed for the other IL-17 cytokines. 
Lester et al.42 found increased IL-17A concentrations in gingival tissue supernatants at sites 
of severe attachment loss where a positive correlation was detected between the tissue level of 
this cytokine and CAL. Increased IL-17 levels in chronic periodontitis patients have been 
reported in other clinical studies.28,35 Indeed, local tissue expression of the IL-17 probably 
contributes to higher amounts of IL-17 detected in GCF of periodontitis patients when compared 
with healthy individuals28,35 and this finding may suggest an important role for IL-17 in the 
pathogenesis of chronic periodontitis. In the present study, GCF/PICF IL-17A, IL-17-F, IL-17E 
levels and IL-17A/IL-17E ratios were similar at all evaluated sites. It has to be conceded that the 
relatively low numbers of samples in different study groups may have a role in this finding, since 
studies with larger GCF sample numbers have reported clear differences in IL-17A and in IL-
17A/IL-17E ratios.28 On the other hand, the IL-17A/IL-17E ratio correlated positively with CAL 
at implant sites in the present study.  
Conclusion 
Within the limitations of this cross sectional study, some interesting data were obtained that may 
be relevant to the differing levels of disease at implants and teeth. It might be concluded that 
peri-implant and periodontal sites in the same patients are similar in many aspects but some 
differences in biomarker levels were seen particularly in IL-1β, RANKL and OPG. Furthermore, 
The biofilm plays a significant role in initiation and progression of peri-implant and 
periodontal diseases. An animal study46 and a human cross-sectional study47 have revealed that 
similar bacterial species are associated with periodontitis and peri-implantitis. Shibli et al.48 
evaluated the supragingival and subgingival microflora and concluded that higher mean counts 
of P. gingivalis, T. denticola and T. forsythia were observed in the peri-implantitis group. 
Canullo et al.49 compared microbiological composition at healthy implants and implants with 
peri-implantitis and while orange complex species (P. intermedia, P. micros, F. nucleatum) were 
prevalent in both groups, their prevalence was higher in the peri-implantitis group. Implant sites 
were reported to be positive for A. actinomycetemcomitans, P. gingivalis, P. intermedia, T. 
forsythia and T. denticola during the 10-days period after surgery.50 Red complex 
microorganisms (P. gingivalis, T. forsythia, T. denticola) were found to be more prevalent at 
peri-implantitis sites than at healthy implants.39 Consistent with previous reports, significantly 
lower amounts of A. naeslundii, P. gingivalis, F. nucleatum and T. forsythia were detected in the 
healthy implant group than the mucositis group. F. nucleatum, P. gingivalis, P. intermedia and T. 
forsythia levels were significantly higher in the peri-implantitis group than the healthy implant 
group.  
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there were differences in the levels of a select number of bacterial species present at implants and 
teeth and at both healthy and diseased sites around implants and the dentition.  
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Figure 1.  
Box and whisker plots showing (A) the amount (B) concentration of IL-1β; (C) the amount,  (D) concentration 
sRANKL; (E) the amount  (F) concentration OPG and the (G) sRANKL:OPG ratio in PICF from Implant sites: 
clinically healthy, with mucositis, with peri-implantitis and in GCF taken from teeth: clinically healthy, gingivitis, 
and periodontitis.  
*Statistically significant differences between implant sites and tooth sites with similar disease categories. 
†Statistically significant differences between the disease categories and the corresponding healthy implant or tooth 
sites.  
†Statistically significant differences between mucositis and peri-implantitis or between gingivitis and periodontitis.  
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Figure 2.  
Box and whisker plots showing (A) the amount, (B) concentration of IL-17A; (C) the amount, (D) concentration of 
IL-17F; (C) the amount, (D) concentration of IL-17E (IL-25) and (G) the IL-17A:IL-17E ratio in PICF from implant 
sites:  clinically healthy (white), with mucositis (light grey), with peri-implantitis and in GCF from tooth sites: 
clinically healthy, gingivitis, and periodontitis.   
*Statistically significant differences between the disease categories and the corresponding healthy implant or tooth 
sites (p<0.05).  
Figure 3.  
The stacked bars represent, in alphabetical order top-bottom, (A) the cumulative copy numbers of microorganisms 
at implant and tooth sites and (B) the cumulative percentage of each organism at tooth and implant sites. Significant 
differences between the sample sites for each organism are indicated.  
* significantly higher at the mucositis than healthy implant sites (p<0.05). 
† significantly higher at the peri-implantitis sites than at the healthy implant sites (p<0.05). 
‡ significantly higher at the gingivitis sites than at the healthy teeth (p<0.05). 
§ significantly higher at the periodontitis sites than at the healthy tooth sites (p<0.05). 
ll significantly higher at the periodontitis sites than at the gingivitis sites (p<0.05). 
¶ significantly lower in the healthy implant samples than in the healthy tooth samples (p<0.05). 
# significantly lower at the mucositis sites than at the gingivitis sites (p<0.05). 
** significantly lower at the peri-implantitis sites than at the periodontitis sites (p<0.05) 
Table 1.  
Clinical parameters recorded in the sampling sites and full-mouth values 
 Implants Teeth 
Clinical 
Parameter 
Healthy Mucositis Peri-implantitis Healthy Gingivitis Periodontitis 
N 19 (15) 20 (15) 19 (15) 19 (15) 12 (10) 8 (6) 
PICF/GCF 
volume (µL) 
0.51 ± 0.48 0.7 ± 0.46 0.72 ± 0.34* 0.27 ± 0.26 0.53 ± 0.34 0.68 ± 0.38* 
PD (mm) 2.09 ± 0.71 2.8 ± 0.77 5.47 ± 2.09† 1.86 ± .57 2.75 ± .51 4.67 ± 0.52† 
CAL (mm) 2.3 ± 0.41 2.8 ± 0.77 6.79 ± 3.43* 1.29 ± 1.1 2.75 ± 2.41* 6.84 ± 2.24* 
PI 0.05 ± 0.23 0.7 ± 0.47 0.89 ± 0.32* 0.33 ± 0.48 0.5 ± 0.45 1.0 ± 0.0* 
KrTW (mm) 3.37 ± 1.26 2. ± 1.56 1.58 ± 1.54 4.88 ± 1.12 3.0 ± 0.8 3.67 ± 0.82 
Full-mouth 
BOP 
0.14 ± 0.10 0.63 ± 0.17† 0.67 ± 0.27† 0.3 ± 0.24 0.4 ± 0.21 0.58 ± 0.12 
Full-mouth PI 0.14 ± 0.10 0.59 ± 0.13† 0.66 ± 0.21† 0.31 ± 0.25 0.4 ± 0.16 0.65 ± 0.05* 
Full-mouth PD 2.42 ± 0.51 2.48 ± 0.3 2.76 ± .42 2.05 ± 0.15 2.0 ± 0.38 2.92 ± 0.2* 
Full-mouth 
CAL 
1.2 ± 0.92 2.33 ± 1.03 2.24 ± 1.43 1.8 ± 1.14 2.0 ± 0.48 1.75 ± 1.99 
Time in 
function 
(months) 
15.11 ± 3.43 21.0 ± 8.6 34.11± 14 0.0 ± 0.0 0.0 ± 0.0 12.0 ± 0.0 
Significantly different from the healthy sites (*P<0.05; †P<0.01) 
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Table 2.  
Spearman correlations between the bacterial counts and clinical parameters 
 Implants Teeth 
Bacteria species PD CAL PI PD CAL PI 
A. actinomycetem -0.082 -0.222* 0.042 0.611† 0.111 0.172 
A. naeslundi -0.015 0.238* 0.229* 0.219 0.327 0.014 
F. nucleatum 0.346† -0.131 0.238* 0.673† 0.039 0.302 
P. gingivalis 0.446† 0.079 0.419† 0.683† 0.134 0.337 
P. intermedia 0.107 0.257* 0.175 0.080 0.017 0.057 
P. oralis -0.097 -0.066 -0.046 0.660† 0.235 0.359 
S. mutans 0.039 -0.171 0.268* -0.249 0.311 -0.202 
S. oralis -0.168 0.208 -0.007 -0.766† -0.169 -0.446 
T. denticola 0.261* -0.011 0.146 0.373 0.192 0.201 
T. forsythia 0.269* -0.030 0.233* 0.595† -0.100 0.302 
Statistically significant correlations  (*P<0.05; †P<0.01) 
Table 3.  
Spearman correlations between bacterial counts and cytokines 
Bacterial species sRANKL OPG IL-1β sRANKL/OPG 
A. actinomycetem -0.228*  0.099       -0.067 -0.241* 
A. naeslundi 0.025 -0.021 0.016 0.130 
F. nucleatum 0.157 -0.104  0.337† 0.171 
P. gingivalis  0.229*   -0.249*  0.384†  0.278† 
P. intermedia  0.356† -0.155  0.278†  0.214* 
P. oralis 0.122 -0.060 0.103 0.045 
S. mutans 0.046 -0.194 0.113 0.128 
S. otalis 0.010 0.079       -0.146         -0.057 
T. denticola  0.246* -0.154  0.272†  0.224* 
T. forsythia  0.239* -0.168  0.261†  0.238* 
V. dispar  0.366†  -0.385†  0.386†  0.284† 
Statistically significant correlations (*P<0.05; †P<0.01) 
∗∗ C1, MIS implant, Savion Isreal 
†† Conelog, Camlog implant, Basel, Switzerland 
‖ Williams, Hu-Friedy, Chicago, IL, USA 
¶ Periopaper®, Proflow Inc., NY, USA 
# Periotron 8000®; Oroflow, NY, USA 
‡‡ Hu-Friedy, Chicago, IL, USA 
†† R&D systems, Abingdon, UK 
‡‡ Peprotech, London, UK 
§§ Peprotech, London, UK 
‖‖ Peprotech, London, UK 
¶¶ Peprotech, London, UK 
## Thermo Fisher, Paisley, UK 
                                                   
‡‡ Peprotech, London, UK 
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*** Epicentre Masterpure, Cambio, Cambridge, UK 
††† NANODROP 1000 Thermo Renfrew, UK 
‡‡‡ CYquant assay system, Invitrogen, Paisley, UK 
§§§ ABI, Invitrogen, Paisley, UK 
‖‖‖ Invitrogen, Paisley, UK 
¶¶¶ MRX3000 Agilent Edinburgh, UK 
### IBM, Armonk, USA 
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